Please type a p	olus sian	(+)	inside	this	box
-----------------	-----------	-----	--------	------	-----

Under the Paperwork Reduction Act of 1995, no persons are

PTO/SB/08A (10-96) or use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.	S. DEPARTMENT OF COMMERCI
collection of information unless it or	ontains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSU STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

C	omplete if Known	`
pplication Number	09/498,704	
Filing Date	02/07/2000	
First Named Inventor	Paul S. Uster	
Group Art Unit	1616	
Examiner Name	Unknown	
Attorney Docket Number	5325-0162 30	

		U.S. PATENT DOCUMENTS									
Cite No.1	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear						
			· · · · · · · · · · · · · · · · · · ·								
	•	- 	· 								
	1										
	· · · · · · · · · · · · · · · · · · ·										
					· · · · · · · · · · · · · · · · · · ·						
	·		 .								
-											
				 							
 i				<u> </u>							
1											
	-										
											
			-	 							
	,										
			No 1 Number Kind Code*	No.1 Number Nila Code of Cited Document	No.1 Number Nind Code of Cited Document						

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Do	cument Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
M	1	wo	96 25147 A	V.	Sequus Pharm. Inc.	08/22/1996		
Tak	2	wo	99 30561 A	7	Nexstar Pharma.	06/24/1999		
1/1	3		00 43045 A	7	Photogen Inc.	07/27/2000		
000								
								₩
		\sqcup				ļ		↓_
		 			<u></u>			╁
		\sqcup			<u> </u>			+-
					-			+

				-	***
Examiner	Kala /	Date	10	07	
Signature	1900	Considered		0	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)

Approve or use through 10/31/99. OMB 0651-0031

Platent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Wind to respond to a splicition of information unless it contains a valid OMB control number.

	ute for form 1449B/PTO		G TA	.04	omplete if Known
				Application Number	09/498,704
INF	ORMATION	D	ISCLOSURE	Filing Date	02/07/2000
STA	TEMENT F	3 Y	APPLICANT	First Named Inventor	Paul S. Uster
0.7	7 E.W. E.W.	- .	A) L.O/((1)	Group Art Unit	1616
	(use as many s	heets	as necessary)	Examiner Name	Unknown
Sheet	I_1	of	1	Attorney Docket Number	5325-0162.30

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
la	1	HARRINGTON ET AL., "Stealth Liposome Encapsulated Iododeoxyuridine (SLIUdR) for Targeted Radiosensitisation in Xenograft Tumours," British J. of Cancer, p. 35, V.78(2)	
		May, 1d9 8	
Examine Signature		Date Considered ()	

considered. Include copy of this form with next communication to applicant.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

EC	L NO. F	09/498	O162.30		INCORMATION DISCLOSURE CITATION					
NOV (INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified)					
ITOY .							several sheet			
CENTE	TE(, et al		APPLICAN			P E SOS	01		
	1615	GROUP	АТЕ У 7, 2000	FILING D			7 2000	NOV		
	<u>.</u>			UMENTS	PATENT DOC	U.S.	EMARKOW	B NOV		
ate	Filing	ubclass	Class	<u> </u>	Name	Date	Document	xaminer		
:iate	If Appro						Number	itial		
		=								
ion	Transla	ubclass	Class S	ry	Count	Date	Document Number			
ion	Transla	ubclass	Class S		PCT	08/22/96	Number WO 96/25147	h		
ion	Transla	Subclass	Class		PCT PCT	08/22/96 06/24/99	Number WO 96/25147 WO 99/30561	4		
ion	Transla	subclass	Class		PCT	08/22/96	Number WO 96/25147	4		
ion	Transla				PCT PCT	08/22/96 06/24/99 07/27/00	Number WO 96/25147 WO 99/30561 WO 00/43045	y l		
	ion in	, Etc.)	nent Pages	ate, Perti	PCT PCT PCT nor, Title, Da , "Stealth JdR) for ta	08/22/96 06/24/99 07/27/00/ Including Aut K., et al idine (SLI umours" Br	Number WO 96/25147 WO 99/30561 WO 00/43045 OTHER ART (I	m		
	ion in	, Etc.)	nent Pages	ate, Perti	PCT PCT PCT nor, Title, Da , "Stealth JdR) for ta	08/22/96 06/24/99 07/27/00/ Including Aut K., et al idine (SLI umours" Br	Number WO 96/25147 WO 99/30561 WO 00/43045 OTHER ART (I	m		
	ion in	, Etc.)	nent Pages	ate, Perti	PCT PCT PCT nor, Title, Da , "Stealth JdR) for ta	08/22/96 06/24/99 07/27/00/ Including Aut K., et al idine (SLI umours" Br	Number WO 96/25147 WO 99/30561 WO 00/43045 OTHER ART (I	In .		
	ion in	, Etc.)	nent Pages	ate, Perti	PCT PCT PCT nor, Title, Da , "Stealth JdR) for ta	08/22/96 06/24/99 07/27/00/ Including Aut K., et al idine (SLI umours" Br	Number WO 96/25147 WO 99/30561 WO 00/43045 OTHER ART (I	In .		
	ion in	, Etc.)	nent Pages	ate, Perti	PCT PCT PCT nor, Title, Da , "Stealth JdR) for ta	08/22/96 06/24/99 07/27/00/ Including Aut K., et al idine (SLI umours" Br	Number WO 96/25147 WO 99/30561 WO 00/43045 OTHER ART (I	M		
	ion in	, Etc.)	nent Pages	ate, Perti	PCT PCT PCT nor, Title, Da , "Stealth JdR) for ta	08/22/96 06/24/99 07/27/00/ Including Aut K., et al idine (SLI umours" Br	Number WO 96/25147 WO 99/30561 WO 00/43045 OTHER ART (I	Ju Ju		
	ion in	, Etc.)	nent Pages ne encaps radiosens	ate, Perti	PCT PCT PCT nor, Title, Da , "Stealth JdR) for ta itish Journ 3).	08/22/96 06/24/99 07/27/00/ Including Aut K., et al idine (SLI umours" Br	Number WO 96/25147 WO 99/30561 WO 00/43045 OTHER ART (I	MINER MINER		

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO. 5325-0162.30

SERIAL NO. 09/498,704

RECEIVED

APPLICANT

Uster, et al.

MAY 1 2000

FILING DATE February 7, 2000 GROUP

1617ECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner	Document	Date	Name	Class	Subclass	Filing Date
Initial	Number					If Appropriate
1/4	4,942,226	07/17/90	Saari			
	5,077,034	12/31/91	Kassis et al.		<u></u>	
	5, 223,263	06/29/93	Hostetler et al.			
	5,728,684	03/17/98	Cheng et al.		_	
1/	5,811,073	09/22/98	Kassis et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translati	Lon
						Yes	No
W	5058879 A	03/09/93	, JP /			Derwent abstract only	
M	95/15154	06/08/95	PCT				
			•				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

[w	Atcher, R.W., et al., "Halogenated Pyrimidines as Radiosensitizers for High-LET Radiation" Radiation Research 117:351-355 (1989).
	Epstein, A.H., et al., "Tumour Radiosensitization with the Halogenated Pyrimidines 5'-bromo- and 5'-iododeoxyuridine" BJR Supplement 24:209-214 (1992).
	Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Hardman, et al. (eds), McGraw-Hill, New York, pp. 1247-1248 (1996).
	Hofer, K.G., "Nouvelles Et Travaux" Bull Cancer (Paris) 67(3):343-353 (1980).
	Mori, A., et al., "Immunotargeting of Liposomes Containing Lipophilic Antitumor Prodrugs" Pharmaceutical Research 10(4):507- 514 (1993).
	Mori, A., et al., "Characterization of Organ-specific Immunoliposomes for Delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model" Cancer Chemother Pharmacol 35:447-456 (1995).

... Scherphof, G.L., et al., "Lipid Flow Phenomena Between Liposomes, Doproteins and Cell Membranes; Applications in Drug Delivery" Liposome Dematics, Braun-Falco, Korting and Maibach (eds), Springer Verlag: Berlin, pp. 11-19 (1992). Scherphof, G.L., et al., "Liposomes in Chemo- and Immunotherapy of Cancer" Lipids 22(11):891-896 (1987). Schwendener, R.A., et al., "5'-0-Palmitoyl- and 3',5'-0-Dipalmitoyl-5-Fluoro-2'-Deoxyuridine - Novel Lipophilic Analogues TPE of 5'-Fluoro-2'-Deoxyuridine: Synthesis, Incorporation into Liposomes and Preliminary Biological Results" Biochemical and DEMAR MAY 1 5 2000 Biophysical Research Communications 126(2):660-666 (1985). Schwendener, R.A., "The Preparation of Large Volumes of Momogeneous, Sterile Liposomes Containing Various Lipophilic Cytostatic Drugs by the Use of a Capillary Dialyzer" *Cancer Drug* Delivery 3(2):123-129 (1986). Shenoy, M.A. and Singh, B.B., "Chemical Radiosensitizers in Cancer Therapy" *Cancer Investigation* 10(06):533-551 (1992). Smolin, G., et al., "Idoxuridine-Liposome Therapy for Herpes Simplex Keratitis" American Journal of Ophthalmology 91:220-225 (1981).Supersaxo, A., et al., "The Antitumour Effect of Lipophilic Derivatives of 5-fluoro-2'-deoxyuridine Incorporated into Liposomes" J Microencapsulation 5(1):1-11(1988). Van Borssum Waalkes, M., et al., "In-vitro Stability and Cytostatic Activity of Liposomal Formulations of 5-fluoro-2'deoxyuridine and its Diacylated Derivatives" Biochimica et Biophysica Acta <u>1148</u>:161-172 (1993). Van Borssum Waalkes, M., et al., "In vivo Distribution and Antitumour Activity of Liposomal 3', 5'-0-dipalmitoyl-5-fluoro-2'-deoxyuridine" J Microencapsulation 9(3):335-346 (1992). Van Borssum Waalkes, M., Lipophilic Derivatives of 5-Fluoro-2'-Deoxyuridine as Liposomal Anticancer Agents pp. 7-159 (1992). Van Borssum Waalkes, M. and Scherphof, G.L., "Liposome-Incorporated 3', 5'-O-Dipalmitoyl-5-Fluoro-2'-Deoxyuridine as a Slow-Release Anti-Tumor Drug Depot in Rat Liver Macrophages" Selective Cancer Therapeutics 6(1):15-22 (1990). Van Borssum Waalkes, M., et al., "Toxicity of Liposomal 3'-5'-0-dipalmitoyl-5-fluoro-2'-deoxyuridine in Mice" Anti-Cancer Drug Design 13:291-305 (1998). DATE CONSIDERED examiner

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.